NASDAQ:AMRN - Amarin Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$16.91 -1.08 (-6.00 %)
(As of 12/9/2018 04:00 PM ET)
Previous Close$16.91
Today's Range$16.68 - $18.15
52-Week Range$2.35 - $23.33
Volume5.76 million shs
Average Volume12.97 million shs
Market Capitalization$4.94 billion
P/E Ratio-67.64
Dividend YieldN/A
Beta0.65
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has collaboration with Mochida Pharmaceutical Co., Ltd. for the development of EPA-Based drug products and indications. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
Previous Symbol
CUSIPN/A
Phone353-1669-9020

Debt

Debt-to-Equity RatioN/A
Current Ratio1.33
Quick Ratio1.05

Price-To-Earnings

Trailing P/E Ratio-67.64
Forward P/E Ratio-46.97
P/E GrowthN/A

Sales & Book Value

Annual Sales$181.10 million
Price / Sales27.30
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.33) per share
Price / Book-51.24

Profitability

EPS (Most Recent Fiscal Year)($0.25)
Net Income$-67,860,000.00
Net Margins-51.15%
Return on EquityN/A
Return on Assets-53.17%

Miscellaneous

Employees241
Outstanding Shares292,320,000
Market Cap$4.94 billion
OptionableOptionable

Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) announced its quarterly earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The biopharmaceutical company earned $55 million during the quarter, compared to the consensus estimate of $60.63 million. The business's revenue was up 16.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.04) earnings per share. View Amarin's Earnings History.

When is Amarin's next earnings date?

Amarin is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Amarin.

What price target have analysts set for AMRN?

5 analysts have issued 1 year price targets for Amarin's stock. Their predictions range from $15.00 to $51.00. On average, they expect Amarin's share price to reach $31.80 in the next year. This suggests a possible upside of 88.1% from the stock's current price. View Analyst Price Targets for Amarin.

What is the consensus analysts' recommendation for Amarin?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. Cantor Fitzgerald analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (12/7/2018)
  • 2. HC Wainwright analysts commented, "We believe that beyond the topline of 25% reduction of MACE score, the robustness of the data is highlighted by the consistency across pre-specified analyses. A key secondary composite, namely 3-point MACE score (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke), which assesses the major CV events (and reflects the most important clinical relevance), showed an even higher reduction of risks at 26% compared to placebo. The clinical benefits as measured by the primary endpoint of MACE score and the key secondary 3-point MACE score are observed across subgroups (statistically significant in the vast majority of the subgroups), which speaks to the validity and robustness of the data." (11/12/2018)
  • 3. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (8/8/2018)

Has Amarin been receiving favorable news coverage?

Press coverage about AMRN stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amarin earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.

Are investors shorting Amarin?

Amarin saw a decline in short interest in November. As of November 15th, there was short interest totalling 11,354,568 shares, a decline of 35.1% from the October 31st total of 17,500,650 shares. Based on an average trading volume of 17,939,623 shares, the days-to-cover ratio is presently 0.6 days. Approximately 3.9% of the shares of the stock are short sold. View Amarin's Current Options Chain.

Who are some of Amarin's key competitors?

Who are Amarin's key executives?

Amarin's management team includes the folowing people:
  • Mr. John F. Thero, Pres, CEO & Director (Age 57)
  • Mr. Michael W. Kalb, CFO, Sr. VP & Assistant Sec. (Age 47)
  • Dr. Steven B. Ketchum, Pres of R&D, Sr. VP and Chief Scientific Officer (Age 53)
  • Mr. Joseph T. Kennedy, Chief Compliance Officer, Exec. VP of Strategic Initiatives, Gen. Counsel and Sec. (Age 50)
  • Ms. Elisabeth Schwartz, Sr. Director of Investor Relations

Who are Amarin's major shareholders?

Amarin's stock is owned by a number of of retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (11.65%), Oracle Investment Management Inc. (2.00%), Sofinnova Ventures Inc (1.78%), Clearbridge Investments LLC (1.27%), BlackRock Inc. (1.16%) and Morgan Stanley (1.10%). Company insiders that own Amarin stock include John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Michael Wayne Kalb and Steven B Ketchum. View Institutional Ownership Trends for Amarin.

Which institutional investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Stonepine Capital Management LLC, Stonepine Capital Management LLC, Sofinnova Ventures Inc, Morgan Stanley, Opaleye Management Inc., Wells Fargo & Company MN and Hsbc Holdings PLC. Company insiders that have sold Amarin company stock in the last year include John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Michael Wayne Kalb and Steven B Ketchum. View Insider Buying and Selling for Amarin.

Which institutional investors are buying Amarin stock?

AMRN stock was acquired by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Clearbridge Investments LLC, Point72 Asset Management L.P., EULAV Asset Management, Rubric Capital Management LP, C WorldWide Group Holding A S, Perceptive Advisors LLC and Oracle Investment Management Inc.. View Insider Buying and Selling for Amarin.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $16.91.

How big of a company is Amarin?

Amarin has a market capitalization of $4.94 billion and generates $181.10 million in revenue each year. The biopharmaceutical company earns $-67,860,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Amarin employs 241 workers across the globe.

What is Amarin's official website?

The official website for Amarin is http://www.amarincorp.com.

How can I contact Amarin?

Amarin's mailing address is 2 Pembroke House Upper Pembroke Street 28-32, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]


MarketBeat Community Rating for Amarin (NASDAQ AMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  577 (Vote Outperform)
Underperform Votes:  349 (Vote Underperform)
Total Votes:  926
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2018 by MarketBeat.com Staff

Featured Article: What is a Swap?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel